Investment Trusts

International Biotechnology Trust

IBT:LSE

International Biotechnology Trust

  • Price (GBX)640.00
  • Today's Change3.00 / 0.47%
  • Shares traded18.00
  • 1 Year change-4.19%
  • Beta0.1836
Data delayed at least 20 minutes, as of May 10 2024 08:02 BST.
More ▼
Total returns on £1000
1Y
Fund/benchmarkChange
PriceInternational Biotechnology Trust (Ordinary Share)+0.46%
NAVInternational Biotechnology Trust (Ordinary Share)+0.63%
Morningstar's BenchmarkNasdaq Biotechnology Index--

Announcements

More ▼

Key statistics

As of last trade International Biotechnology Trust (IBT:LSE) traded at 640.00, -9.09% below its 52-week high of 704.00, set on Feb 28, 2024.
52-week range
Today
548.00Oct 27 2023704.00Feb 28 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Shares outstanding37.68m
Market cap241.89m GBP
Total assets302.78m GBP
Total expense ratio1.44%
High646.00
Low640.00
Previous close637.00
Average volume63.83k
YTD Change-0.31%
Beta0.1836
Diluted NAV (est)707.31
Diluted NAV (last pub)709.61
Premium/Discount-9.55%
Net Gearing+11.85%
Annual div (ADY)28.10 GBX
Annual div yield (ADY)4.38%
Div ex-dateDec 21 2023
Div pay-dateJan 26 2024
Data delayed at least 20 minutes, as of May 10 2024 08:02 BST.
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.